MX2018014184A - Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda. - Google Patents
Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda.Info
- Publication number
- MX2018014184A MX2018014184A MX2018014184A MX2018014184A MX2018014184A MX 2018014184 A MX2018014184 A MX 2018014184A MX 2018014184 A MX2018014184 A MX 2018014184A MX 2018014184 A MX2018014184 A MX 2018014184A MX 2018014184 A MX2018014184 A MX 2018014184A
- Authority
- MX
- Mexico
- Prior art keywords
- pure
- receptor antagonist
- nmda
- acetylcholinesterase inhibitors
- triple combination
- Prior art date
Links
- 108091005435 5-HT6 receptors Proteins 0.000 title abstract 3
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 3
- 229940099433 NMDA receptor antagonist Drugs 0.000 title abstract 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003751 serotonin 6 antagonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se relaciona con una combinación de antagonista del receptor de 5-HT6 puro, inhibidor de acetilcolinesterasa y antagonista del receptor de NMDA. Asimismo, la presente invención se relaciona con antagonistas del receptor de 5-HT6 (5-HT6R) o sales farmacéuticamente aceptables de los mismos en combinación con o como un adjunto del inhibidor de acetilcolinesterasa y el antagonista del receptor de N-metil-D-aspartato (NMDA) y su uso en el tratamiento de trastornos cognitivos. La presente invención proporciona además la composición farmacéutica que contiene dicha combinación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641017204 | 2016-05-18 | ||
| PCT/IB2016/054672 WO2017199070A1 (en) | 2016-05-18 | 2016-08-03 | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018014184A true MX2018014184A (es) | 2019-02-25 |
Family
ID=56896730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014184A MX2018014184A (es) | 2016-05-18 | 2016-08-03 | Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11253514B2 (es) |
| EP (1) | EP3458039B1 (es) |
| JP (1) | JP6629464B2 (es) |
| KR (1) | KR102016120B1 (es) |
| CN (1) | CN109152751A (es) |
| AU (1) | AU2016407426B2 (es) |
| BR (1) | BR112018073410A2 (es) |
| CA (1) | CA3023836C (es) |
| CY (1) | CY1123644T1 (es) |
| DK (1) | DK3458039T3 (es) |
| EA (1) | EA038087B1 (es) |
| ES (1) | ES2815555T3 (es) |
| HK (1) | HK1258022A1 (es) |
| HR (1) | HRP20201412T1 (es) |
| HU (1) | HUE052077T2 (es) |
| IL (1) | IL262920B (es) |
| LT (1) | LT3458039T (es) |
| MA (1) | MA45002B1 (es) |
| MD (1) | MD3458039T2 (es) |
| MX (1) | MX2018014184A (es) |
| NZ (1) | NZ747797A (es) |
| PL (1) | PL3458039T3 (es) |
| PT (1) | PT3458039T (es) |
| RS (1) | RS60849B1 (es) |
| SG (1) | SG11201809726UA (es) |
| SI (1) | SI3458039T1 (es) |
| WO (1) | WO2017199070A1 (es) |
| ZA (1) | ZA201807310B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201913104QA (en) * | 2017-07-03 | 2020-01-30 | Suven Life Sciences Ltd | New uses of a pure 5-ht 6 receptor antagonist |
| WO2021111320A1 (en) * | 2019-12-02 | 2021-06-10 | Suven Life Sciences Limited | Methods for treating behavioral and psychological symptoms in patients with dementia |
| EP4069232A1 (en) | 2019-12-02 | 2022-10-12 | Suven Life Sciences Limited | Treating behavioral and psychological symptoms in dementia patients |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005528431A (ja) * | 2002-05-31 | 2005-09-22 | ハー・ルンドベック・アクチエゼルスカベット | アルツハイマー病を治療するためのｎｍｄａ−アンタゴニスト及びアセチルコリンエステラーゼ阻害剤の組み合わせ物 |
| ATE401307T1 (de) * | 2002-11-28 | 2008-08-15 | Suven Life Sciences Ltd | N-arylsulfonyl-2-substituierte indole mit affinität zum serotonin rezeptor, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen |
| KR101463190B1 (ko) * | 2010-01-05 | 2014-11-18 | 수벤 라이프 사이언시스 리미티드 | ５ｈｔ６ 수용체 리간드인 술폰 화합물 |
| RS56323B1 (sr) * | 2013-12-02 | 2017-12-29 | Suven Life Sciences Ltd | Proces za masovnu proizvodnju monohidrata 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1h-indol dimezilata |
| US9840482B2 (en) * | 2014-04-19 | 2017-12-12 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
-
2016
- 2016-08-03 CN CN201680085589.7A patent/CN109152751A/zh active Pending
- 2016-08-03 HU HUE16763575A patent/HUE052077T2/hu unknown
- 2016-08-03 MX MX2018014184A patent/MX2018014184A/es unknown
- 2016-08-03 MD MDE20190349T patent/MD3458039T2/ro unknown
- 2016-08-03 MA MA45002A patent/MA45002B1/fr unknown
- 2016-08-03 SI SI201630909T patent/SI3458039T1/sl unknown
- 2016-08-03 ES ES16763575T patent/ES2815555T3/es active Active
- 2016-08-03 NZ NZ747797A patent/NZ747797A/en unknown
- 2016-08-03 BR BR112018073410-1A patent/BR112018073410A2/pt not_active Application Discontinuation
- 2016-08-03 KR KR1020187035888A patent/KR102016120B1/ko active IP Right Grant
- 2016-08-03 SG SG11201809726UA patent/SG11201809726UA/en unknown
- 2016-08-03 US US16/097,752 patent/US11253514B2/en active Active
- 2016-08-03 WO PCT/IB2016/054672 patent/WO2017199070A1/en unknown
- 2016-08-03 DK DK16763575.4T patent/DK3458039T3/da active
- 2016-08-03 RS RS20201045A patent/RS60849B1/sr unknown
- 2016-08-03 CA CA3023836A patent/CA3023836C/en active Active
- 2016-08-03 PL PL16763575T patent/PL3458039T3/pl unknown
- 2016-08-03 LT LTEP16763575.4T patent/LT3458039T/lt unknown
- 2016-08-03 PT PT167635754T patent/PT3458039T/pt unknown
- 2016-08-03 EA EA201892528A patent/EA038087B1/ru unknown
- 2016-08-03 EP EP16763575.4A patent/EP3458039B1/en active Active
- 2016-08-03 AU AU2016407426A patent/AU2016407426B2/en active Active
- 2016-08-03 JP JP2018559327A patent/JP6629464B2/ja active Active
-
2018
- 2018-10-31 ZA ZA2018/07310A patent/ZA201807310B/en unknown
- 2018-11-11 IL IL262920A patent/IL262920B/en active IP Right Grant
-
2019
- 2019-01-10 HK HK19100393.2A patent/HK1258022A1/zh unknown
-
2020
- 2020-09-03 HR HRP20201412TT patent/HRP20201412T1/hr unknown
- 2020-09-04 CY CY20201100834T patent/CY1123644T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| SG10201804868PA (en) | Compounds for the inhibition of indoleamine-2,3-dioxygenase | |
| MX2016011632A (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| MX2022013612A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
| MX2017014192A (es) | Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. | |
| MX2019002180A (es) | Moduladores alostericos positivos del receptor m1 muscarinico. | |
| WO2016109217A3 (en) | Btk inhibitors | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| TW201713341A (en) | Compositions and methods of treating a neurodegenerative disease | |
| TW201613577A (en) | Pharmaceutical combinations | |
| MX2016002580A (es) | Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. | |
| EA201792057A1 (ru) | Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы | |
| WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
| MX2020010568A (es) | Derivados de urea ciclica fusionada como antagonista de crhr2. | |
| MX2018014185A (es) | Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa. | |
| CY1123644T1 (el) | Τριπλος συνδυασμος καθαρων ανταγωνιστων του υποδοχεα 5-ητ6, αναστολεων της ακετυλοχολινεστερασης και του ανταγωνιστη του υποδοχεα nmda | |
| TN2018000214A1 (en) | Alkyl dihydroquinoline sulfonamide compounds | |
| MX2018013969A (es) | Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. | |
| MX2018007511A (es) | Compuestos de alquinil dihidroquinolina sulfonamida. | |
| PH12021550143A1 (en) | Pyridopyrimidines as histamine h4-receptor inhibitors | |
| PH12017501736A1 (en) | Indole derivatives | |
| MX2019001698A (es) | Combinacion triple de agonistas inversos del receptor de histamina 3, inhibidores de la acetilcolinestearasa y antagonistas del receptor nmda. | |
| NZ750150A (en) | Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors | |
| TN2017000248A1 (en) | Cgrp antagonist peptides | |
| MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. |